Cargando…
Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment
SIMPLE SUMMARY: Several treatments are available for patients with advanced hepatocellular carcinoma (HCC), and it is important to understand patients’ treatment priorities and goals regarding such treatment options. In a survey study, we explored 200 patients’ preferences for six different features...
Autores principales: | Li, Daneng, Tan, Ruoding, Hernandez, Sairy, Reilly, Norelle, Bussberg, Cooper, Mansfield, Carol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001043/ https://www.ncbi.nlm.nih.gov/pubmed/36900262 http://dx.doi.org/10.3390/cancers15051470 |
Ejemplares similares
-
Adolescent and caregiver preferences for juvenile idiopathic arthritis treatment: a discrete-choice experiment
por: McErlane, Flora, et al.
Publicado: (2023) -
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
por: Li, Daneng, et al.
Publicado: (2022) -
Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment
por: Serbin, Michael, et al.
Publicado: (2023) -
Patient Preferences for Treating “OFF” Episodes in Parkinson’s Disease: A Discrete Choice Experiment
por: Thach, Andrew, et al.
Publicado: (2021) -
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
por: Salem, Riad, et al.
Publicado: (2021)